163915-96-6

Basic information

• Product Name: Benzenemethanol, 2-nitro-, methanesulfonate (ester)
• Synonyms: Benzenemethanol, 2-nitro-, methanesulfonate (ester)
• CAS NO: 163915-96-6
• Molecular Formula: C8H9NO5S
• Molecular Weight: 231.229
• Mol File: 163915-96-6.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Benzenemethanol, 2-nitro-, methanesulfonate (ester)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzenemethanol, 2-nitro-, methanesulfonate (ester)(163915-96-6)
• EPA Substance Registry System: Benzenemethanol, 2-nitro-, methanesulfonate (ester)(163915-96-6)

Safety Data

• Hazardous Substances Data: 163915-96-6(Hazardous Substances Data)

Upstream product

• 552-89-6 2-nitro-benzaldehyde 
• 612-25-9 2-Nitrobenzyl alcohol 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 363138-96-9 (E)-2-[Methyl-(2-nitro-benzyl)-amino]-but-2-enedioic acid dimethyl ester 
• 210288-67-8 (2S)-2,3,4,5-tetrahydro-7-iodo-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid 
• 1904-69-4 2-amino-N-methylbenzylamine 
• 95668-86-3 1-(azidomethyl)-2-nitrobenzene 
• 22162-51-2 1-(2-Nitrobenzyl)-2-pyrrolecarboxaldehyde 
• 146624-40-0 Ethyl 1-[[3-(trifluoromethyl)-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxylate 
• 146624-41-1 1-[[3-(Trifluoromethyl)-2-[2-[[(trifluoromethyl)sulphonyl]amino]phenyl]-5-benzofuranyl]methyl]-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxylic acid 
• 146625-02-7 ethyl 4-cyclopropyl-2-ethyl-1-<<2-(2-nitrophenyl)-3-(2,2,2-trifluoromethyl)-5-benzofuranyl>methyl>-1H-imidazole-5-carboxylate 
• 146625-03-8 ethyl 1-<<2-(2-aminophenyl)-3-(2,2,2-trifluoromethyl)-5-benzofuranyl>methyl>-4-cyclopropyl-2-ethyl-1H-imidazole-5-carboxylate 
• 146015-54-5 5-(bromomethyl)-2-(2-nitrophenyl)-3-(trifluoromethyl)-3-benzofuran 
• 146015-53-4 5-methyl-2-(2-nitrophenyl)-3-(trifluoromethyl)-3-benzofuran 
• 56222-08-3 (2-nitrobenzyl)methylamine 
• 146015-51-2 2,2,2-trifluoro-1-<5-methyl-2-<(2-nitrophenyl)methoxy>phenyl>ethanone 

Relevant articles and documents

Bromobenzofuran-based non-peptide antagonists of angiotensin II: GR138950, a potent antihypertensive agent with high oral bioavailability

We have identified GR138950, a potent antagonist of the angiotensin II receptor with high oral bioavailability, as our second drug candidate to GR117289. Using GR117289, a compound with moderate bioavailability (20%) in man as a lead, we pursued a strategy aimed at enhancing bioavailability. The strategy was based on SAR established around the diacid GR117289, and from this, it was proposed that a monoacid, in particular a trifluoromethanesulfonamide, should be better absorbed after oral administration and have enhanced oral bioavailability. This led to the identification of GR138950, a potent antihypertensive agent in the renal hypertensive rat, causing sustained falls in blood pressure after oral administration. Oral bioavailability of GR138950 in rats and dogs is high, confirming that GR138950 is well absorbed after oral administration. Moreover, the low plasma clearance and long plasma half-life suggest that this compound will be suitable for once a day administration. Furthermore, the preliminary data indicate that the high bioavailability of GR138950 seen in rats and dogs translates to man. These results demonstrate clearly that GR138950 has the potential to be a clinically effective antihypertensive agent. Further studies are in progress to evaluate GR138950 in the treatment of hypertension.

Preparation method 1 - (2 -nitrobenzyl) pyrrole -2 - formaldehyde

The invention discloses a preparation method of 1 - (2 -nitrobenzyl) pyrrole -2 - formaldehyde, which comprises the following steps: S1. 1 Nitrobenzene-based methanol, triethylamine and dichloromethane are added to the reaction kettle 2 - stirred at - 5 °

Novel leucine ureido derivatives as aminopeptidase N inhibitors using click chemistry

The over-expression of aminopeptidase N on diverse malignant cells is associated with the tumor angiogenesis and metastasis. In this report, one new series of leucine ureido derivatives containing the triazole moiety was designed, synthesized and evaluated as APN inhibitors. Among them, compound 13v showed the best APN inhibition with an IC50 value of 0.089 ± 0.007 μM, which was two orders of magnitude lower than that of bestatin (IC50 = 9.4 ± 0.5 μM). Compound 13v also showed dose-dependent anti-angiogenesis activities. Even at the lower concentration (10 μM), compound 13v presented similar anti-angiogenesis activity compared with bestatin at 100 μM in both the human umbilical vein endothelial cells (HUVECs) capillary tube formation assay and the rat thoracic aorta rings test. Moreover, compared with bestatin, 13v exhibited comparable, if not better in vivo anti-metastasis activity in a mouse H22 pulmonary metastasis model.